Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.

Next Previous
Trial Profile

A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benzgalantamine (Primary) ; Galantamine
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors AlphaCognition

Most Recent Events

  • 07 Oct 2021 According to an AlphaCognition media release, top-line data read-out from BABE study is scheduled for late Q1 2022.
  • 24 Mar 2018 Status changed to active, no longer recruiting.
  • 24 Mar 2018 Primary endpoint (Adaptive tracking performance (22 mg GLN-1062 vs Placebo)) has been met as per the results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top